MARATHON PATENT GROUP, INC. (NASDAQ:MARA) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
As previously reported in a Current Report on Form 8-K filed by Marathon Patent Group, Inc., a Nevada corporation (the “Company”) with the Securities and Exchange Commission (“SEC”) on August 15, 2017, and on September 9, 2017, the Company entered into a unit purchase agreement (the “Unit Purchase Agreement”) with certain accredited investors providing for the sale up to $5,500,000 (the “Offering”) of 5% secured convertible promissory notes (the “Convertible Notes”), which are convertible into shares of the Corporation’s common stock (“Common Stock”), and a five year warrant (the “Warrants”) to purchase shares of Common Stock with an exercise price of $0.30 per share (the “Warrant Shares”). The Company previously issued $3,623,700 of the Convertible Notes and the Warrants, which are convertible and exercisable for up to an aggregate of 54,355,500 shares of the Common Stock.
On September 28, 2017, at the final closing of the Offering to the Unit Purchase Agreement, the Company sold an additional $1,876,300 of the Convertible Notes and the Warrants, which are convertible and exercisable for up to an aggregate of 28,144,500 shares of Common Stock., thereby selling the maximum amount of the Offering of $5,500,000.
The foregoing descriptions of the terms of the Unit Purchase Agreement, the Convertible Note and the Warrant are qualified in their entirety by reference to the full text of the Unit Purchase Agreement, Convertible Note and the Warrant, copies of which are filed as Exhibits 4.1, 4.2 and 10.1, respectively, to the Company’s Current Report filed with the SEC on August 15, 2017, and are incorporated by reference herein.
| Item 2.01 | Completion of Acquisition or Disposition of Assets. |
As previously reported in the Company’s Current Report on Form 8-K filed with the SEC on August 25, 2017, the Company entered into a Retention Agreement dated August 22, 2017 (the “Retention Agreement”) with Doug Croxall, the Company’s Chief Executive Officer. As a condition to the Retention Agreement, the Company agreed to transfer and assign to Mr. Croxall, the Company’s Chief Executive Officer, one hundred (50%) percent of its beneficial ownership of the shares of common stock of 3D Nanocolor Corp. (the “3D Nanocolor Shares”).
On September 29, 2017, to the Retention Agreement, the Company executed an Irrevocable Stock Power to transfer and assign the 3D Nanocolor Shares to Mr. Croxall.
| Item 3.02 | Unregistered Sales of Equity Securities. |
The information set forth in Item 1.01 is incorporated by reference herein.
The issuance of the securities described above was completed in accordance with the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Such offers and sales were made solely to “accredited investors” under Rule 506 and were made without any form of general solicitation and with full access to any information requested by the investor regarding the Company or the securities to be issued in the Exchange. This disclosure does not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor will there be any sales of these securities by the Company in any state or jurisdiction in which the offer, solicitation or sale would be unlawful.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Retention Agreement with Doug Croxall
to the Retention Agreement, Doug Croxall’s last day of employment with the Company as Chief Executive Officer shall be the earlier of (i) October 1, 2017, and (ii) the occurrence of a Change of Control (as defined in the Retention Agreement). On September 29, 2017, the Board of Directors of the Company (the “Board”) approved the deferment of Mr. Croxall’s last day of employment with the Company until October 31, 2017. In addition, Mr. Croxall has advised the Company that he may pursue other business activities, including activities related to 3D Nanocolor Corp. and the Board has represented to him that they would not assert that such outside activities would be deemed to be a breach of Mr. Croxall’s fiduciary duty or a conflict of interest.
Board Compensation
Also, on September 29, 2017, the Board approved the issuance of shares of the Company’s restricted common stock to the Company’s 2017 Equity Incentive Plan (the “Options”), to each of the Company’s four (4) independent directors, as follows: 350,000 shares to Mr. Merrick Okamoto, 150,000 shares to Mr. Edward Kovalik, 150,000 shares to Mr. David Lieberman and 150,000 shares to Mr. Christopher Robichaud. In addition, each director shall receive a cash compensation of $1,000 per month, plus $3,000 per annum for each position as Chairman of a Board subcommittee and $1,000 per annum for membership of a Board Subcommittee.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 29, 2017, the Company held a special meeting of shareholders (the “Meeting”). As of the record date for the Meeting, 29,492,066 shares of common and preferred stock, on an as converted basis, were issued and outstanding. A total of 15,138,499 shares of common and preferred stock, constituting a quorum, were present and accounted for at the Meeting. At the Meeting, the Company’s stockholders approved the following proposals:
| (i) | The approval of the First Amendment to Amended and Restated Revenue Sharing and Securities Purchase Agreement and Restructuring Agreement dated August 3, 2017, by and between the Company and certain subsidiaries of the Company, and DBD Credit Funding LLC, as supplemented on September 25, 2017, and the contribution of certain of the Company’s intellectual property to a newly created special purpose entity as described in the First Amendment and Restructuring Agreement; |
The proposal was approved and the votes were cast as follows:
| For | Against | Abstain |
| 14,976,476 | 149,384 | 12,639 |
| (ii) | The approval of the issuance of more than 19.99% of the total issued and outstanding shares of the Company’s common stock to the sale of 5% secured convertible promissory notes in the aggregate principal amount of up to $5,500,000 with warrants to purchase shares of the Company’s common stock, or up to 82,500,000 shares of the Company’s common stock issuable upon conversion of the aforementioned securities, to the Company’s private placement, as required by the agreements related to such private placement; |
The issuance was approved and the votes were cast as follows:
| For | Against | Abstain |
| 14,901,966 | 234,162 | 2,371 |
| (iii) | The approval of the Company’s 2017 Equity Incentive Plan, including the reservation of 10,000,000 shares of Common Stock thereunder; |
The proposal was approved and the votes were cast as follows:
| For | Against | Abstain |
| 14,090,205 | 565,294 | 483,000 |
| (iv) | The approval of the issuance of 2,394,000 shares of common stock to purchasers of securities in the Company’s April 21, 2017 offering in exchange for warrants to purchase 2,280,000 shares of common stock to separate exchange agreements, dated July 16, 2017, by and among the Company and the purchasers of securities in the aforementioned offering; |
The issuance was approved and the votes were cast as follows:
| For | Against | Abstain |
| 14,707,290 | 179,109 | 252,100 |
| (v) | The approval of the Company to transact such other business as may be properly brought before the Special Meeting and any adjournments thereof any adjournments thereof. |
The proposal was approved and the votes were cast as follows:
| For | Against | Abstain |
| 14,500,532 | 209,750 | 428,217 |
| Item 9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
About MARATHON PATENT GROUP, INC. (NASDAQ:MARA)
Marathon Patent Group Inc. (MARA) is engaged in acquiring patents and patent rights from owners or other ventures. The Company monetizes its portfolio of patents and patent rights by entering into license discussions. The Company owns around 378 United States and foreign patents, and patent rights across a range of technologies and markets. The Company owns around 22 patent applications across a range of technologies and markets.
